Download Medical Notes on 2019 R&D Achievements New product launches, clinical trial activity, and investments

2019 R&D Achievements New product launches, clinical trial activity, and investments Medical Notes

About This Presentation

Description:This report titled, “Innovation in Diabetes Care Technology” is by the IQVIA Institute and assesses the current status in the R&D of medicines, especially coronavirus COVID-19 pandemic outbreak. The report provides an analysis of the number of initiated clinical trials and insight into the success rate of products after development. The current state of innovation is explored by examining the record numbers of new active substances (NAS) launched in 2019, analyzing their features and development path, as well as the important contributions of both NAS and non-NAS therapies. The levels of life science venture capital activity and large pharma R&D spend grew. This report also details the expanding pipeline of therapies still under development, examines trends among therapy areas, and analyzes the growing number of Next- Generation Biotherapeutic products, which include cell, gene, and nuc

Tags:COVID-19, pandemic, clinical trials, new product development, pharma R and D, pharma pharmaceutical

Published on: Jul 20, 2020 | Views : 1729 | Downloads : 0

Comment

Transcript

No transcript available for this presentation

User Presentation
Related Presentations

Global Medicine Spending and Usage Trends - Outlook to 2024

About : I am a passionate medical marketing professional with hands on experience in healthcare digital marketing.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : India
Website :

Global Medicine Spending and Usage Trends - Outlook to 2024

The Impact of COVID-19 on Cancer Treatment in Spain

Matrix of Human Lifespan and Wellness

REJUVENATION MEDICINE

Life after cancer

The Pharmaceutical Industry in Europe – Facts and Figure

Indian API (Active Pharmaceutical Ingredient) Industry - Reaching The Full Potential

A Blueprint for Improving the Security of the USA Pharmaceutical Supply Chain

The Impact of the COVID-19 Pandemic on Global Pharmaceutical Growth

Orphan Drugs in the United States - Exclusivity, Pricing and Treated Populations

HEALTH A TO Z